Naltrexone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318302

CAS#: 16590-41-3 (free)

Description: Naltrexone is a drug that reverses the effects of opioids and is used primarily in the management of alcohol dependence and opioid dependence. It should not be confused with naloxone or nalorphine, which are used in emergency cases of opioid overdose.


Price and Availability

Size
Price

100mg
USD 550
Size
Price

200mg
USD 950
Size
Price

Naltrexone, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318302
Name: Naltrexone
CAS#: 16590-41-3 (free)
Chemical Formula: C20H23NO4
Exact Mass: 341.1627
Molecular Weight: 341.4009
Elemental Analysis: C, 70.36; H, 6.79; N, 4.10; O, 18.75


Related CAS #: 16590-41-3 (free)   16676-29-2 (HCl)  

Synonym: Naltrexone, Revia, Depade, Vivitrol, Celupan, EN-1639A, EN 1639A, EN1639A

IUPAC/Chemical Name: (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one

InChi Key: DQCKKXVULJGBQN-XFWGSAIBSA-N

InChi Code: InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1

SMILES Code: C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O


Technical Data

Appearance:
Off-white to yellow solid powder.

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Christou GA, Kiortsis DN. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones (Athens). 2015 Jul-Sep;14(3):370-5. doi: 10.14310/horm.2002.1600. Review. PubMed PMID: 26188223.

2: Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557. Epub 2014 May 23. Review. PubMed PMID: 24661324.

3: Taylor R, Raffa RB, Pergolizzi JV. Opioid formulations with sequestered naltrexone: a perspective review. Ther Adv Drug Saf. 2014 Jun;5(3):129-37. doi: 10.1177/2042098614526769. Review. PubMed PMID: 25083268; PubMed Central PMCID: PMC4110852.

4: Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems. J Control Release. 2014 Jun 10;183:154-66. doi: 10.1016/j.jconrel.2014.03.046. Epub 2014 Apr 2. Review. PubMed PMID: 24704710.

5: Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28. Review. PubMed PMID: 24766397.

6: Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19. Review. PubMed PMID: 24754973.

7: Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Review. PubMed PMID: 24526250; PubMed Central PMCID: PMC3962576.

8: Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev. 2014 Mar;33(2):115-28. doi: 10.1111/dar.12095. Epub 2013 Dec 3. Review. PubMed PMID: 24299657.

9: Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2014 Feb 21;2:CD010410. doi: 10.1002/14651858.CD010410.pub2. Review. PubMed PMID: 24558033.

10: Kunøe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol. 2014 Feb;77(2):264-71. doi: 10.1111/bcp.12011. Review. PubMed PMID: 23088328; PubMed Central PMCID: PMC4014017.

11: Raffa RB, Taylor R Jr, Pergolizzi JV Jr. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use? Expert Opin Drug Saf. 2014 Feb;13(2):181-90. doi: 10.1517/14740338.2013.841136. Epub 2013 Nov 11. Review. PubMed PMID: 24206269.

12: Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014 Sep 18;8:1419-27. doi: 10.2147/DDDT.S55587. eCollection 2014. Review. PubMed PMID: 25258511; PubMed Central PMCID: PMC4174046.

13: Hulse GK. Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x. Review. PubMed PMID: 22946873; PubMed Central PMCID: PMC3853523.

14: Syed YY, Keating GM. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review. PubMed PMID: 24018540.

15: Thorsell A. The μ-opioid receptor and treatment response to naltrexone. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Review. PubMed PMID: 23543091.

16: Jarosz J, Miernik K, Wąchal M, Walczak J, Krumpl G. Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2013 May;39(3):144-60. doi: 10.3109/00952990.2013.796961. Review. PubMed PMID: 23721530.

17: Gahr M, Kölle MA, Schönfeldt-Lecuona C. [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy]. Nervenarzt. 2013 May;84(5):584-9. doi: 10.1007/s00115-012-3633-3. Review. German. PubMed PMID: 22892944.

18: Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013 Feb;108(2):275-93. doi: 10.1111/j.1360-0443.2012.04054.x. Epub 2012 Oct 17. Review. PubMed PMID: 23075288; PubMed Central PMCID: PMC3970823.

19: Jones HE, Chisolm MS, Jansson LM, Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction. 2013 Feb;108(2):233-47. doi: 10.1111/j.1360-0443.2012.03811.x. Epub 2012 Apr 4. Review. PubMed PMID: 22471668.

20: Bieńkowski P. [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence]. Psychiatr Pol. 2013 Jan-Feb;47(1):117-26. Review. Polish. PubMed PMID: 23888749.